GLP-1 Receptor Agonists Show Promise in Treating Neurodegenerative Diseases
Researchers have explored the potential of glucagon-like peptide-1 (GLP-1) receptor agonists in treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s. A recent study by Paul Edison, MD, PhD, at Imperial College London found that GLP-1 analogs reduced neuroinflammation and tau tangle deposits in animal models of Alzheimer’s disease. Studies have shown promising results with GLP-1 … Read more